» Articles » PMID: 32486283

Reporter Replicons for Antiviral Drug Discovery Against Positive Single-Stranded RNA Viruses

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2020 Jun 4
PMID 32486283
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Single-stranded positive RNA ((+) ssRNA) viruses include several important human pathogens. Some members are responsible for large outbreaks, such as Zika virus, West Nile virus, SARS-CoV, and SARS-CoV-2, while others are endemic, causing an enormous global health burden. Since vaccines or specific treatments are not available for most viral infections, the discovery of direct-acting antivirals (DAA) is an urgent need. Still, the low-throughput nature of and biosafety concerns related to traditional antiviral assays hinders the discovery of new inhibitors. With the advances of reverse genetics, reporter replicon systems have become an alternative tool for the screening of DAAs. Herein, we review decades of the use of (+) ssRNA viruses replicon systems for the discovery of antiviral agents. We summarize different strategies used to develop those systems, as well as highlight some of the most promising inhibitors identified by the method. Despite the genetic alterations introduced, reporter replicons have been shown to be reliable systems for screening and identification of viral replication inhibitors and, therefore, an important tool for the discovery of new DAAs.

Citing Articles

RNA replication-independent, DNA linearization-dependent expression of reporter genes from a SARS-CoV-2 replicon-encoding DNA in human cells.

Friedhoff R, Elfayres G, Merindol N, Desgagne-Penix I, Berthoux L PLoS One. 2024; 19(8):e0300491.

PMID: 39150942 PMC: 11329111. DOI: 10.1371/journal.pone.0300491.


Development and validation of Mayaro virus with luciferase reporter genes as a tool for antiviral assays.

Marinho M, Zhang Y, Cassani N, Santos I, Costa Oliveira A, Pereira A Heliyon. 2024; 10(13):e33885.

PMID: 39071632 PMC: 11283106. DOI: 10.1016/j.heliyon.2024.e33885.


Development of a Cell Culture Model for Inducible SARS-CoV-2 Replication.

Wang X, Zhu Y, Wu Q, Jiang N, Xie Y, Deng Q Viruses. 2024; 16(5).

PMID: 38793589 PMC: 11125939. DOI: 10.3390/v16050708.


Delivery of Spherical and Cylindrical Reconstituted Virus-like Particles Containing the Same Self-Amplifying mRNA.

Karan S, Duran-Meza A, Chapman A, Tanimoto C, Chan S, Knobler C Mol Pharm. 2024; 21(6):2727-2739.

PMID: 38709860 PMC: 11250921. DOI: 10.1021/acs.molpharmaceut.3c01105.


Cell type dependent stability and virulence of a recombinant SARS-CoV-2, and engineering of a propagation deficient RNA replicon to analyze virus RNA synthesis.

Wang L, Guzman M, Munoz-Santos D, Honrubia J, Ripoll-Gomez J, Delgado R Front Cell Infect Microbiol. 2023; 13:1268227.

PMID: 37942479 PMC: 10628495. DOI: 10.3389/fcimb.2023.1268227.


References
1.
P Monath T . Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012; 11(4):427-48. DOI: 10.1586/erv.12.6. View

2.
Aubry F, Nougairede A, de Fabritus L, Querat G, Gould E, de Lamballerie X . Single-stranded positive-sense RNA viruses generated in days using infectious subgenomic amplicons. J Gen Virol. 2014; 95(Pt 11):2462-2467. PMC: 4202267. DOI: 10.1099/vir.0.068023-0. View

3.
Bok K, Cavanaugh V, Matson D, Gonzalez-Molleda L, Chang K, Zintz C . Inhibition of norovirus replication by morpholino oligomers targeting the 5'-end of the genome. Virology. 2008; 380(2):328-37. PMC: 3703767. DOI: 10.1016/j.virol.2008.08.007. View

4.
Horscroft N, Lai V, Cheney W, Yao N, Wu J, Hong Z . Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Antivir Chem Chemother. 2005; 16(1):1-12. DOI: 10.1177/095632020501600101. View

5.
Norder H, De Palma A, Selisko B, Costenaro L, Papageorgiou N, Arnan C . Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res. 2011; 89(3):204-18. DOI: 10.1016/j.antiviral.2010.12.007. View